CELZ Stock Forecast: Creative Medical Technology Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.40
−8.14% on the day

The median 12-month analyst price target for Creative Medical Technology Holdings, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$3.1M
Ticker Nerd rank
16/ 100
Median analyst target
$20
Analysts covering
1
Revenue$0.0
Operating income−$1.6M
Net income−$1.5M
Free cash flow−$1.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.5%
1M
−46.4%
YTD
−79.4%
1Y
−85.2%
From 52W high
−85.2%
From 52W low
0.0%
$0.40
$2.74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Creative Medical Technology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
16/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
63
Accruals
38
Momentum
30
Revisions
26
Issuance
24
Quality
22
Volatility
9
Value
3

Growth (63): Sales and profits are climbing, and climbing faster than before.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CELZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26CELZHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$20
Low
$20
Median
$20
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Feb 2022Roth CapitalInitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CELZ.

Market Radar

This page is one stock. Monday covers all of them.

CELZ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CELZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Creative Medical Technology Holdings, Inc. returned −85.2% against +6.9% for the S&P 500, dividends included.

CELZ vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CELZS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1019.3×

Cheaper than 1% of US stocks

Price / book
0.4×

Cheaper than 88% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−118.7%

Higher than 12% of US stocks

Return on assets
−73.2%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Creative Medical Technology Holdings, Inc. has a market value of $3.1M.

  • Revenue in the twelve months to 30 June 2026: $3K.

  • Net income over the same four quarters: −$6.0M, a −201285.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.0M.

  • Creative Medical Technology Holdings, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 4.7M.

  • Creative Medical Technology Holdings, Inc. employs 4 people — $750.0 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CELZ and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELZCreative Medical Technology Holdings, Inc.$3.1M16
JAGXJaguar Health, Inc.$3.0M50
SKYESkye Bioscience, Inc.$3.1M50
AZTRAzitra, Inc.$3.1M26
NRSNNeurosense Therapeutics Ltd.$3.2M3
KPRXKiora Pharmaceuticals, Inc.$3.2M60
APREAprea Therapeutics, Inc.$3.2M20

Take a look at CELZ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Creative Medical Technology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CELZ

What is the CELZ stock price forecast for 2026-2027?

The median 12-month analyst price target for Creative Medical Technology Holdings, Inc. is $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELZ stock a buy right now?

Of the 1 analyst covering Creative Medical Technology Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Creative Medical Technology Holdings, Inc. 16 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELZ?

As at 21 Nov 2026, Creative Medical Technology Holdings, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (63 of 100).

Will CELZ stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $20, and Ticker Nerd's factor model ranks Creative Medical Technology Holdings, Inc. 16 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELZ stock forecast for 2030?

No analyst covering Creative Medical Technology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has CELZ stock performed over the past year?

Creative Medical Technology Holdings, Inc. returned -85.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Creative Medical Technology Holdings, Inc. do?

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on regenerative medicine and novel biological therapeutics. The company develops products and programs across immunology, endocrinology, urogynecology, urology, neurology, and orthopedics, with an emphasis on stem cell-based and cell-derived approaches.

Company

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on regenerative medicine and novel biological therapeutics. The company develops products and programs across immunology, endocrinology, urogynecology, urology, neurology, and orthopedics, with an emphasis on stem cell-based and cell-derived approaches. Its portfolio includes therapies and platforms such as CaverStem, FemCelz, StemSpine, ImmCelz, and AlloStem, which are designed for a range of conditions including sexual health, spinal disorders, immune-related diseases, and other unmet medical needs. Creative Medical Technology Holdings, Inc. serves a specialized role in the healthcare market by advancing regenerative technologies from development into commercial use and clinical evaluation. Headquartered in Phoenix, Arizona, the company concentrates on translating biomedical research into targeted treatment options for patients and clinicians.

CEO Mr. Timothy Warbington · 4 employees · United States · https://www.creativemedicaltechnology.com